ziftomenib,bevacizumab,cisplatin,mobocertinib,ipilimumab,bms-986218,bevacizumab,carboplatin,atezolizumab,paclitaxel,osimertinib,furmonertinib,amivantamab,sintilimab,amivantamab,acalabrutinib,nivolumab,pemetrexed,pembrolizumab,durvalumab
roche,kura oncology,eli lilly,arrivent,merck,etana,genmab,takeda,astrazeneca,bms,janssen,allist,innovent biologics
['sclc', 'nsclc']
great discussion by dr. reiss highlighting opportunities and challenges in the field of egfr-mutant nsclc. novel drugs/combinations on the horizon and the field will likely further advances in the near future. #asco23 
Thoracic Medical Oncologist at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM